Peter Attia· MD
I really do see there's there's there's what I would say a related class of therapies the metabolism targeted therapies um and epigenetic targeted therapies which have been exploding um in terms of understanding how you know the blueprint the genetic blueprint is sort of folded up and unfolded um The Regulators of that um and the way in which cancers um many cancers like need to figure out how to you know co-opt or you know take over um the the function of some of those um folders and unfolder um and so there's been real explosion in novel U very early in development drugs in that class